Skip to main content

Advertisement

SpringerLink
Log in

Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The objectives of this phase I study were to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary efficacy of intraperitoneally administered irinotecan (CPT-11) in gastric cancer patients with peritoneal seeding.

Experimental design

Gastric adenocarcinoma patients with surgical biopsy proven peritoneal seeding were enrolled at the time of surgery. Prior to IP chemotherapy, patients underwent palliative gastrectomy and CAPD catheter insertion in which CPT-11 was administered on postoperative day 1. The IP CPT-11 was initiated at 50 mg/m2, which was escalated to 100, 150, 200, 250, and 300 mg/m2. IP CPT-11 chemotherapy was repeated every 3 weeks.

Results

Seventeen patients received a total of 56 cycles at five different CPT-11 dose levels. The DLTs were neutropenic fever, neutropenia, and diarrhea. At the dose level 2 (100 mg/m2), there were one DLTs in one of the first cohort of three patients, but no DLTs at the second cohort of this level. At the dose level 5 (250 mg/m2), two DLTs were detected in the first two patients; thus, the accrual was stopped resulting in the recommended dose of IP CPT-11 of 200 mg/m2. Median progression-free survival was 8.6 months (95% CI, 5.9,11.2), and median overall survival was 15.6 months (95% CI, 8.4,22.8). Pharmacokinetic results of the study showed that the C max of peritoneal SN-38 was achieved earlier than that of plasma SN-38.

Conclusions

Intraperitoneally administered CPT-11 was feasible and tolerable. Further, phase II study of IP CPT-11 in gastric cancer patients with peritoneal seeding is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10(Suppl 3):49–58

    Article  CAS  PubMed  Google Scholar 

  2. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955

    Article  CAS  PubMed  Google Scholar 

  3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  CAS  PubMed  Google Scholar 

  4. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C (2004) Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie digestive group study—FFCD 9803. J Clin Oncol 22:4319–4328

    Article  CAS  PubMed  Google Scholar 

  5. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267–272

    Article  CAS  PubMed  Google Scholar 

  6. Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P, Ducreux M (2004) Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 15:1558–1565

    Article  CAS  PubMed  Google Scholar 

  7. Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 139:20–26

    Article  CAS  PubMed  Google Scholar 

  8. Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P (1998) Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 42:165–170

    Article  CAS  PubMed  Google Scholar 

  9. Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K et al (1992) Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339:629–631

    Article  CAS  PubMed  Google Scholar 

  10. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715–1720

    CAS  PubMed  Google Scholar 

  11. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K (2005) Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 92:1850–1854

    Article  CAS  PubMed  Google Scholar 

  12. Kodera Y, Ito Y, Ito S, Ohashi N, Mochizuki Y, Yamamura Y, Koike M, Fujiwara M, Nakanishi H, Nakao A (2007) Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology 54:960–963

    CAS  PubMed  Google Scholar 

  13. Makrin V, Lev-Chelouche D, Even Sapir E, Paran H, Rabau M, Gutman M (2005) Intraperitoneal heated chemotherapy affects healing of experimental colonic anastomosis: an animal study. J Surg Oncol 89:18–22

    Article  CAS  PubMed  Google Scholar 

  14. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, Southwestern oncology group, and Eastern cooperative oncology group. J Clin Oncol 19:1001–1007

    CAS  PubMed  Google Scholar 

  15. Maruyama M, Nagahama T, Yuasa Y (1999) Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis. Anticancer Res 19:4187–4191

    CAS  PubMed  Google Scholar 

  16. Maruyama M, Toukairin Y, Baba H, Kure N, Nagahama T, Ebuchi M (2001) Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers. Gan To Kagaku Ryoho 28:1505–1507

    CAS  PubMed  Google Scholar 

  17. Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M (2005) Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 92:2122–2128

    Article  CAS  PubMed  Google Scholar 

  18. Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M (1998) Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology. J Clin Oncol 16:2733–2738

    CAS  PubMed  Google Scholar 

  19. Topuz E, Basaran M, Saip P, Aydiner A, Argon A, Sakar B, Tas F, Uygun K, Bugra D, Aykan NF (2002) Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study. Am J Clin Oncol 25:619–624

    Article  PubMed  Google Scholar 

  20. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743

    Article  PubMed  Google Scholar 

  21. Yonemura Y, Endou Y, Bando E, Kuno K, Kawamura T, Kimura M, Shimada T, Miyamoto K, Sasaki T, Sugarbaker PH (2004) Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Lett 210:189–196

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, Korea

    Moon Ki Choi, Young Suk Park, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim & Won Ki Kang

  2. Medical Science Research Center, Dongguk University, Seoul, Korea

    Byung-Jin Ahn

  3. Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Korea

    Dong-Seok Yim

  4. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Sung Kim, Tae Sung Sohn, Jae Hyung Noh & Jin Seok Heo

Authors
  1. Moon Ki Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Byung-Jin Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-Seok Yim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Young Suk Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tae Sung Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jae Hyung Noh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jin Seok Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jeeyun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Se Hoon Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Joon Oh Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ho Yeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Won Ki Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young Suk Park.

Additional information

M. K. Choi and B. J. Ahn contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, M.K., Ahn, BJ., Yim, DS. et al. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. Cancer Chemother Pharmacol 67, 5–11 (2011). https://doi.org/10.1007/s00280-010-1272-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1272-6

Keywords

Search

Navigation